Proper induction of Th1 immunity is required for effective immunotherapy of bladder cancer with the bacillus Calmette-Guérin (BCG). Interleukin-10 (IL-10) downregulates the Th1 immune response and is associated with BCG therapy failure. We evaluated BCG plus IL-10 blocking antibodies and found that this combination therapy induces enhanced Th1 immune responses and anti-bladder cancer immunity in preclinical animal models.
No takes yet. Share an insight, caveat, or question.
Yi Luo (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: